Researchers from Clayton Foundation Laboratories (San Diego, CA, USA) have utilized mouse models of Alzheimer’s to test the effects of increasing neuregulin 1.
Browsing: amyloid beta
Recent research using a novel tau ligand demonstrates that amyloid interacts with hippocampal and cortical tau to induce neurodegeneration. Tau imaging offers the opportunity to stage Alzheimer’s disease preclinically.
In an early stage clinical trial, scientists have demonstrated that the new antibody drug, Aducanumab, clears beta-amyloid plaques and slows cognitive decline in Alzheimer’s patients.
This article reviews the field of amyloid-beta immunotherapy for the treatment of Alzheimer’s disease.
Researchers at the University of Cambridge (UK) have uncovered new information about the mechanism underlying the build up of amyloid plaques within the brains of Alzheimer’s disease patients.
Comparison of brain amyloid levels with spinal fluid amyloid may provide a new way of identifying early signs of Alzheimer’s disease.
Preclinical study highlights potential role of amyloid-beta in fighting brain infections.
We delve in to one of the most talked about journal articles of last month, discussing key findings and take-home implications.
Researchers demonstrate that amyloid precursor proteins may lead to endosome enlargement, contributing to early Alzheimer’s disease pathologies.
New research indicates that positron emission tomography (PET) scans could be used to identify tau within the brain and may help in developing effective staged disease therapeutics.